Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis, Postmenopausal | 25 | 2024 | 386 | 8.990 |
Why?
|
| Bone Density Conservation Agents | 37 | 2024 | 773 | 8.910 |
Why?
|
| Teriparatide | 30 | 2022 | 225 | 8.890 |
Why?
|
| Bone Density | 45 | 2024 | 3468 | 3.990 |
Why?
|
| Osteoporosis | 21 | 2024 | 1580 | 2.770 |
Why?
|
| Parathyroid Hormone-Related Protein | 6 | 2021 | 331 | 2.410 |
Why?
|
| Alendronate | 10 | 2023 | 171 | 2.400 |
Why?
|
| Bone Remodeling | 14 | 2019 | 575 | 2.280 |
Why?
|
| Osteoporotic Fractures | 8 | 2022 | 401 | 2.170 |
Why?
|
| Testosterone | 19 | 2020 | 2420 | 1.630 |
Why?
|
| Aromatase Inhibitors | 8 | 2013 | 491 | 1.440 |
Why?
|
| Spinal Fractures | 4 | 2020 | 696 | 1.250 |
Why?
|
| Goserelin | 5 | 2020 | 129 | 1.090 |
Why?
|
| Nitriles | 6 | 2009 | 956 | 1.030 |
Why?
|
| Radius | 4 | 2020 | 422 | 1.000 |
Why?
|
| Bone Resorption | 6 | 2019 | 723 | 0.990 |
Why?
|
| Triazoles | 6 | 2009 | 911 | 0.990 |
Why?
|
| Estradiol | 10 | 2016 | 2020 | 0.980 |
Why?
|
| Diphosphonates | 8 | 2023 | 623 | 0.970 |
Why?
|
| Bone and Bones | 10 | 2020 | 2575 | 0.960 |
Why?
|
| Hypogonadism | 6 | 2009 | 799 | 0.910 |
Why?
|
| Parathyroid Hormone | 5 | 2017 | 1801 | 0.840 |
Why?
|
| Tibia | 4 | 2020 | 1077 | 0.820 |
Why?
|
| Drug Therapy, Combination | 13 | 2020 | 6489 | 0.790 |
Why?
|
| Fractures, Bone | 6 | 2024 | 1947 | 0.740 |
Why?
|
| Collagen Type I | 12 | 2020 | 592 | 0.740 |
Why?
|
| Androstenedione | 5 | 2002 | 131 | 0.700 |
Why?
|
| Femur Neck | 6 | 2021 | 309 | 0.640 |
Why?
|
| Libido | 2 | 2020 | 121 | 0.630 |
Why?
|
| Procollagen | 7 | 2016 | 185 | 0.570 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 374 | 0.550 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2019 | 780 | 0.530 |
Why?
|
| Critical Pathways | 1 | 2019 | 476 | 0.520 |
Why?
|
| Postmenopause | 7 | 2021 | 2461 | 0.520 |
Why?
|
| Phosphates | 3 | 2012 | 786 | 0.510 |
Why?
|
| Fibroblast Growth Factors | 3 | 2012 | 879 | 0.480 |
Why?
|
| Absorptiometry, Photon | 8 | 2020 | 1725 | 0.460 |
Why?
|
| Hypoparathyroidism | 1 | 2013 | 120 | 0.420 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2014 | 744 | 0.400 |
Why?
|
| Citalopram | 1 | 2014 | 403 | 0.390 |
Why?
|
| Anabolic Agents | 2 | 2012 | 247 | 0.390 |
Why?
|
| Aged | 43 | 2021 | 163280 | 0.380 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2016 | 838 | 0.370 |
Why?
|
| Peptides | 11 | 2016 | 4409 | 0.370 |
Why?
|
| Glucocorticoids | 3 | 2012 | 2107 | 0.360 |
Why?
|
| Body Composition | 4 | 2013 | 2401 | 0.340 |
Why?
|
| Muscle Strength | 1 | 2013 | 592 | 0.340 |
Why?
|
| Drug Resistance | 1 | 2015 | 1609 | 0.340 |
Why?
|
| Middle Aged | 43 | 2021 | 213383 | 0.330 |
Why?
|
| Humans | 82 | 2024 | 744343 | 0.320 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2014 | 712 | 0.310 |
Why?
|
| Osteocalcin | 5 | 2011 | 273 | 0.290 |
Why?
|
| Hypercalcemia | 1 | 2009 | 409 | 0.280 |
Why?
|
| Lumbar Vertebrae | 6 | 2020 | 1848 | 0.280 |
Why?
|
| Health | 1 | 2009 | 394 | 0.280 |
Why?
|
| Calcium | 6 | 2023 | 5756 | 0.280 |
Why?
|
| Female | 39 | 2024 | 380194 | 0.280 |
Why?
|
| Drug Substitution | 3 | 2019 | 281 | 0.270 |
Why?
|
| Aromatase | 1 | 2005 | 146 | 0.260 |
Why?
|
| Ergocalciferols | 2 | 2015 | 110 | 0.220 |
Why?
|
| Placebos | 2 | 2020 | 1676 | 0.220 |
Why?
|
| Single-Blind Method | 2 | 2017 | 1590 | 0.210 |
Why?
|
| Treatment Outcome | 15 | 2020 | 63114 | 0.200 |
Why?
|
| Double-Blind Method | 8 | 2017 | 12026 | 0.200 |
Why?
|
| Radiography | 3 | 2020 | 7023 | 0.200 |
Why?
|
| Peptide Fragments | 6 | 2016 | 5097 | 0.200 |
Why?
|
| Etidronic Acid | 1 | 2000 | 64 | 0.190 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 57776 | 0.190 |
Why?
|
| Osteogenesis Imperfecta | 1 | 2020 | 83 | 0.180 |
Why?
|
| RANK Ligand | 3 | 2012 | 326 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2020 | 10943 | 0.180 |
Why?
|
| Androgen Antagonists | 4 | 2012 | 1377 | 0.170 |
Why?
|
| Vitamin D | 2 | 2012 | 3223 | 0.170 |
Why?
|
| Estrogens | 2 | 2004 | 1566 | 0.170 |
Why?
|
| Leuprolide | 1 | 2001 | 321 | 0.170 |
Why?
|
| Hip | 2 | 2019 | 257 | 0.160 |
Why?
|
| Area Under Curve | 3 | 2013 | 1654 | 0.160 |
Why?
|
| Freedom | 1 | 2018 | 69 | 0.150 |
Why?
|
| Genetic Markers | 2 | 2016 | 2634 | 0.150 |
Why?
|
| Male | 39 | 2020 | 350118 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 20129 | 0.150 |
Why?
|
| Injections, Subcutaneous | 4 | 2020 | 666 | 0.140 |
Why?
|
| Professional Practice | 1 | 2019 | 326 | 0.140 |
Why?
|
| Porosity | 1 | 2017 | 362 | 0.140 |
Why?
|
| Eunuchism | 1 | 2016 | 19 | 0.140 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 426 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2004 | 3798 | 0.140 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2008 | 548 | 0.130 |
Why?
|
| Imidazoles | 2 | 2023 | 1206 | 0.130 |
Why?
|
| Androgens | 1 | 2003 | 1281 | 0.130 |
Why?
|
| Cosmetics | 1 | 2016 | 97 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 4933 | 0.120 |
Why?
|
| Prostatic Neoplasms | 6 | 2012 | 11124 | 0.120 |
Why?
|
| Gastroenterology | 1 | 2000 | 536 | 0.120 |
Why?
|
| Gonads | 1 | 2014 | 109 | 0.120 |
Why?
|
| Vitamin D Deficiency | 2 | 2015 | 1343 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 2916 | 0.110 |
Why?
|
| Lipids | 1 | 2005 | 3305 | 0.110 |
Why?
|
| Orthopedics | 1 | 2022 | 904 | 0.110 |
Why?
|
| Spine | 2 | 2019 | 1144 | 0.110 |
Why?
|
| Sex Factors | 1 | 2007 | 10397 | 0.110 |
Why?
|
| Bone Development | 2 | 2007 | 483 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 1125 | 0.110 |
Why?
|
| Calcitriol | 2 | 2006 | 298 | 0.110 |
Why?
|
| Hormones | 2 | 2009 | 889 | 0.110 |
Why?
|
| Risk Factors | 7 | 2020 | 72290 | 0.110 |
Why?
|
| Dietary Supplements | 3 | 2015 | 3297 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 39050 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 4 | 2022 | 9274 | 0.100 |
Why?
|
| Drug Monitoring | 2 | 2019 | 956 | 0.090 |
Why?
|
| Adiposity | 1 | 2020 | 1807 | 0.090 |
Why?
|
| Estrone | 2 | 2002 | 240 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2013 | 1959 | 0.090 |
Why?
|
| Medication Adherence | 2 | 2020 | 2063 | 0.090 |
Why?
|
| Drugs, Investigational | 1 | 2012 | 214 | 0.090 |
Why?
|
| Collagen | 3 | 2020 | 2689 | 0.090 |
Why?
|
| Aging | 3 | 2020 | 8664 | 0.090 |
Why?
|
| Adult | 17 | 2016 | 214055 | 0.090 |
Why?
|
| Administration, Cutaneous | 2 | 2020 | 711 | 0.090 |
Why?
|
| Administration, Oral | 3 | 2002 | 3913 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2012 | 1524 | 0.090 |
Why?
|
| Biological Availability | 1 | 2009 | 397 | 0.080 |
Why?
|
| Multivariate Analysis | 4 | 2012 | 12245 | 0.080 |
Why?
|
| Inpatients | 3 | 2023 | 2518 | 0.070 |
Why?
|
| Prostatic Diseases | 1 | 2007 | 56 | 0.070 |
Why?
|
| Sarcopenia | 1 | 2012 | 368 | 0.070 |
Why?
|
| Population Groups | 1 | 2008 | 209 | 0.070 |
Why?
|
| Endpoint Determination | 1 | 2009 | 601 | 0.070 |
Why?
|
| Osteosarcoma | 1 | 2012 | 881 | 0.070 |
Why?
|
| Menopause | 1 | 2014 | 1626 | 0.070 |
Why?
|
| Public Health | 1 | 2019 | 2603 | 0.070 |
Why?
|
| Testis | 1 | 2009 | 803 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2009 | 600 | 0.070 |
Why?
|
| Young Adult | 6 | 2016 | 56430 | 0.070 |
Why?
|
| Causality | 1 | 2012 | 1275 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2009 | 1205 | 0.060 |
Why?
|
| Time Factors | 4 | 2019 | 40075 | 0.060 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 1782 | 0.060 |
Why?
|
| Osteogenesis | 2 | 2021 | 1299 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 2274 | 0.060 |
Why?
|
| Osteoprotegerin | 1 | 2005 | 176 | 0.060 |
Why?
|
| Steroids | 1 | 2009 | 930 | 0.060 |
Why?
|
| Risk | 2 | 2015 | 9687 | 0.060 |
Why?
|
| Vitamins | 1 | 2012 | 1622 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 3508 | 0.060 |
Why?
|
| Epitestosterone | 1 | 2002 | 3 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 2278 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 15165 | 0.050 |
Why?
|
| Control Groups | 1 | 2002 | 105 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 595 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 9959 | 0.050 |
Why?
|
| Femur | 1 | 2008 | 1297 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 3870 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 707 | 0.050 |
Why?
|
| Androsterone | 1 | 2001 | 14 | 0.050 |
Why?
|
| Etiocholanolone | 1 | 2001 | 7 | 0.050 |
Why?
|
| Glucuronides | 1 | 2001 | 20 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 3386 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2015 | 3864 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2013 | 3279 | 0.050 |
Why?
|
| Estranes | 1 | 2000 | 2 | 0.050 |
Why?
|
| Nandrolone | 1 | 2000 | 17 | 0.050 |
Why?
|
| Dihydrotestosterone | 1 | 2001 | 190 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 8642 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2005 | 1155 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 2219 | 0.050 |
Why?
|
| Insulin | 1 | 2015 | 6580 | 0.050 |
Why?
|
| Penile Erection | 1 | 2020 | 97 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 871 | 0.050 |
Why?
|
| Nonprescription Drugs | 1 | 2000 | 116 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 3229 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2023 | 545 | 0.040 |
Why?
|
| Drug Contamination | 1 | 2000 | 147 | 0.040 |
Why?
|
| Gels | 1 | 2020 | 427 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2009 | 2684 | 0.040 |
Why?
|
| Body Fat Distribution | 1 | 2020 | 244 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2003 | 1792 | 0.040 |
Why?
|
| United States | 4 | 2019 | 69872 | 0.040 |
Why?
|
| Creatinine | 1 | 2023 | 1919 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2001 | 865 | 0.040 |
Why?
|
| Orchiectomy | 2 | 2009 | 474 | 0.040 |
Why?
|
| Injections | 1 | 2020 | 840 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2005 | 2263 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2012 | 7729 | 0.040 |
Why?
|
| Models, Biological | 1 | 2013 | 9583 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2022 | 1530 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6365 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2015 | 39 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2005 | 3200 | 0.030 |
Why?
|
| Amino Acids | 1 | 2001 | 1736 | 0.030 |
Why?
|
| Calcifediol | 1 | 2015 | 166 | 0.030 |
Why?
|
| Homeostasis | 1 | 2005 | 3340 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 3778 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 2924 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 1741 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2008 | 25043 | 0.030 |
Why?
|
| Acid Phosphatase | 1 | 2011 | 143 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 11725 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 13989 | 0.020 |
Why?
|
| Boston | 2 | 2015 | 9313 | 0.020 |
Why?
|
| Cell Count | 1 | 2014 | 1856 | 0.020 |
Why?
|
| Cognition | 1 | 2007 | 6770 | 0.020 |
Why?
|
| Urinalysis | 2 | 2002 | 369 | 0.020 |
Why?
|
| Substance Abuse Detection | 2 | 2002 | 283 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 2759 | 0.020 |
Why?
|
| Immunoassay | 1 | 2012 | 752 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 976 | 0.020 |
Why?
|
| Animals | 2 | 2012 | 168757 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 610 | 0.020 |
Why?
|
| Massachusetts | 1 | 2020 | 8663 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2020 | 77449 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2011 | 1726 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2008 | 623 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2886 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 1157 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2014 | 2504 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2020 | 40561 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4468 | 0.010 |
Why?
|
| Quality of Life | 1 | 2004 | 12804 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2001 | 9239 | 0.010 |
Why?
|
| Linear Models | 1 | 2012 | 5952 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 4665 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 29063 | 0.010 |
Why?
|
| Protein Precursors | 1 | 2002 | 1154 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 15540 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 10180 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2000 | 2203 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 18370 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 20947 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 13881 | 0.010 |
Why?
|
Concepts
(230)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(28)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_